Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

With this partnership, Profil Institute will use Rosa's pharmacokinetic/pharmacodynamic (PK/PD) and physiologically-based PK/PD (PhysioPD™) modeling and simulation technology as a component of its clinical study designs and data interpretations.  Profil Institute, focused on the disease areas of diabetes and obesity, uses specialized clinical research methods, including first-in-patient studies, automated glucose clamp studies, and methods to assess body composition and turnover rates of certain metabolites.  Rosa brings extensive experience in modeling diabetes and obesity in support of early-phase preclinical and clinical programs. Rosa's models will be used to simulate drug effects and trial outcomes to further optimize study designs and to derive scientific and clinical insight from the clinical trial data.

"Combining our proven disease-specific expertise with Rosa's highly advanced simulation technology gives our customers immeasurable value through the most meaningful study design, successful study execution and verifiable data interpretation," said Dr. Marcus Hompesch, Profil Institute CEO. "With the addition of Rosa's modeling and simulation technology, we further enhance our scientific leadership and research capabilities, generating unprecedented standards and added value for early phase clinical research programs in diabetes and obesity."

"This partnership combines deep disease area expertise, powerful simulation technology, and unique study capabilities to address the central issue faced by all drug developers – how to separate successful and unsuccessful drugs as early as possible in the development process," said Ron Beaver, Ph.D., CEO and Founder of Rosa.  "Together, we can deliver greater scientific insight to Profil Institute's customers regarding the viability of their diabetes or obesity drug candidates."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New treatment strategy targets somatostatin to prevent blood sugar drops in type 1 diabetes